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Editorial Comment
Borderline Myocarditis on Initial
Endomyocardial Biopsy:
No-Man's-Land No More?*
STEPHEN M. FACTOR, MD, FACC
Bronx, New York
The decade of the 1980s has seen significant improvement in
the diagnosis of patients with myocarditis. Two related
events account for the enhanced recognition of this condi-
tion: 1) greater utilization of right ventricular endomyocar-
dial biopsy in patients with the onset of heart failure either
unexplained by underlying cardiac disease or of relatively
acute onset; and 2) standardization of the morphologic
criteria employed to diagnose myocarditis. The so-called
Dallas criteria, originally developed in 1984 by a group of
cardiac pathologists at a consensus conference, was finally
published in 1987 (1), although the basic schema had spread
widely by word of mouth before the report appeared in print.
Thus, for 5 years, the Dallas criteria have been in use by
numerous clinical centers during which time their utility has
been tested.
The Dallas criteria for diagnosis of myocarditis. The cri-
teria address the morphologic features of idiopathic myo-
carditis in a simplified fashion, by disregarding possible
pathogenic mechanisms (e.g., viral or immunologic causes,
or both), temporal relations (e.g., acute, subacute or chronic
disease) and prognostic implications. Three primary descrip-
tive categories were defined: 1) active myocarditis with an
inflammatory infiltrate associated with morphologic evi-
dence of myocyte necrosis or damage in the absence of
ischemia or other specific cause; 2) borderline myocarditis,
an indeterminate category in which there is an interstitial
inflammatory infiltrate but no myocyte necrosis or damage;
and 3) no myocarditis, in which there is an absence of
inflammation and a variety of changes ranging from normal
to features consistent with cardiomyopathy (e.g., myocyte
hypertrophy and interstitial fibrosis). Of these categories,
borderline myocarditis is the most difficult to evaluate' it,
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probably has been the major source of diagnostic confusion
since the Dallas criteria were developed.
The present study. The issue of borderline myocarditis,
and how patients who have such a diagnosis on the basis of
an initial endomyocardial biopsy should be managed, is the
focus of the report by Dec et al. (2) in this issue of the
Journal. The authors retrospectively analyzed their experi-
ence over a 6 year period with 384 patients, and they
identified 28 who underwent a second biopsy shortly after
their initial right ventricular biopsy was nondiagnostic of
myocarditis. The rationale for rebiopsy was the impression
that these patients had inflammatory myocardial disease
based on clinical signs and symptoms, but the focal inflam-
matory process presumably was not sampled with the first
biopsy. Of these 28 patients, 6 had the diagnosis of border-
line myocarditis, and 4 ultimately had myocarditis on the
repeat biopsy; the second biopsy was not positive for
myocarditis in any of the other 22 patients without border-
line changes.
What conclusions, ifany, can we draw from this study?
1. It appears to me that several real and implied lessons
are apparent in these data, even though the patient group is
small and the study was performed retrospectively. A diag-
nosis of four additional cases of myocarditis is not an
insignificant number, especially when three of the patients
responded to immunosuppressive therapy, although treat-
ment was neither randomized nor controlled.
2. As indicated in the authors' analysis of left versus right
ventricular sampling, there was discordance in only 1of the
17 patients so studied. This would seem to support the view
that the technically easier and safer right ventricular septal
biopsy adequately samples left ventricular disease.
3. The findings validate the utility oftissue versus clinical
diagnosis. As the authors state, "'borderline' myocarditis
on initial biopsy was the only clinical or histologic finding
predictive of myocarditis on subsequent biopsy."
Indications for rebiopsy. Because myocarditis is often a
multifocal disease and increased tissue sampling may maxi-
mize the detection of inflammatory foci, should rebiopsy be
contemplated for any patient with the acute onset of unex-
plained heart failure and a negative initial biopsy? The
answer is no, based on the lack of correlation with clinical
variables reported by Dec et al. (2), and increased awareness
of the pathophysiology of cardiomyopathy (3). Clinical esti-
mates of disease acuity are not very accurate, and the
clinical indicators of myocarditis are virtually nonexistent. A
patient with compensated congestive cardiomyopathy who
has sudden decompensation may present with acute symp-
toms that resemble myocarditis. Conversely, a patient with
myocarditis may have silent disease, or may present primar-
ily with arrhythmias rather than heart failure (4). Short-term
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clinical signs and symptoms are often misleading, and, thus,
biopsy is the only means to determine the presence of
myocarditis. A negative biopsy, particularly if it shows
evidence of myocellular hypertrophy and fibrosis consistent
with cardiomyopathy, is not likely to be positive on repeat
even if the patient has acute symptoms. However, a diagno-
sis of borderline myocarditis on initial biopsy is more likely
to be positive on the repeat study because inflammation
without myocyte necrosis is often seen around foci of overt
myocarditis.
Implications. Thus, the report by Dec et al, (2), despite
the limited sample size, presents valuable information that
can be used by cardiologists and pathologists who deal with
the borderline biopsy. Although one is hesitant to generalize
on the basis of only six patients, it appears that the original
recommendation proposed empirically in the Dallas criteria
has been validated: patients with borderline myocarditis
should undergo repeat biopsy, if this procedure is clinically
indicated. Knowledge in the field of endomyocardial biopsy
and myocarditis accrues slowly and incrementally. At least,
with this study in this issue of the Journal, some preliminary
steps have been taken to cross the no-man's-land of our
ignorance.
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